Aphexda
Payments companies reported to CMS as associated with Aphexda. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Aphexda, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Aphexda
These are the largest totals companies reported as associated with Aphexda. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Zachary Crees | Saint Louis, MO | Medical Oncology | $20,797.50 |
| Henry Fung | Philadelphia, PA | Hematology & Oncology | $19,479.96 |
| Stephan Grupp | Philadelphia, PA | Pediatric Hematology-Oncology | $17,645.51 |
| Akshay Sharma | Memphis, TN | Pediatric Hematology-Oncology | $12,722.50 |
| Michael Grimley | Cincinnati, OH | Pediatric Hematology-Oncology | $11,812.50 |
| John Manis | Boston, MA | Hematology & Oncology | $10,500.00 |
| Kris Mahadeo | Durham, NC | Pediatric Hematology-Oncology | $8,250.00 |
| Timothy Driscoll | Durham, NC | Pediatric Hematology-Oncology | $7,500.00 |
| Julie Kanter Washko | Birmingham, AL | Pediatric Hematology-Oncology | $5,625.00 |
| Edmund Waller | Atlanta, GA | Hematology (Internal Medicine) | $5,112.50 |
Prescribed Aphexda?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.